Report : Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type (Generic Drugs, Branded Drugs); Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others); Application (HIV, Hepatitis, Virus Influenza, Herpes, Other Applications) and Geography
According to our new market research study on “Anti - Viral Therapies Market to 2027 - Global Analysis and Forecast - by Type, Mechanism of Action, and End User,” the market is expected to reach US$ 76,282.63 million by 2027 from US$ 40,589.79 million in 2019; it is estimated to grow at a CAGR of 8.3% from 2020 to 2027. The report highlights trends prevailing in the global anti - viral therapies market and the drivers and restraints pertaining to the market growth.
Based on type, the global anti - viral therapies market is segmented into generic drugs and branded drugs. The generic drugs segment is estimated to register a higher CAGR in the market during 2020–2027. Rising demand for low-cost drugs, growing number of FDA-approved generic drugs, rising adoption in emerging nations, and patent expiry of various branded products are the factors boosting the market for the generic drugs segment.
The global anti - viral therapies market growth is mainly attributed to factors such as increasing R&D expenditure in pharmaceutical companies and rising government support for research activities and clinical trials. However, high drug development cost hinders the growth of the market.
AbbVie Inc.; Abbott; Astrazeneca; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma are among the leading companies operating in the anti - viral therapies market.
The Report Segments Global Anti - Viral Therapies Market as Follows:
By Mechanism of Action